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Abstract
Although systemic lupus erythematosus
(SLE) has traditionally been considered a
disease of women, men may also be affected.
Thirty of 261 patients (12%) with SLE seen in
this hospital were men. Arthritis was less
common as a first symptom in the men,
although this group of patients had discoid
lesions and serositis more often than the
women. During the follow up a lower incidence
of arthritis and malar rash and a higher
incidence ofother skin complications including
discoid lesions and subcutaneous lupus
erythematosus was found in the men. The
incidence of nephropathy, neurological
disease, thrombocytopenia, vasculitis, and
serositis, was similar in the two groups. No
significant immunological differences were
found between men and women. These
features indicate that severalgender associated
clinical differences may be present in patients
with SLE.
(Ann Rheum Dis 1992; 51: 1050-1052)
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Systemic lupus erythematosus (SLE) is a clin-
ically heterogeneous autoimmune disease of
unk-nown aetiology. One of its most striking
characteristics is its higher prevalence among
young women, men rarely being affected.' Sex
distribution before puberty and late in life does
not show this marked female preponderance,
however.2 Additionally, androgens confer a
protective effect in experimental murine lupus.3
Some workers therefore consider that sex
affects the susceptibility to and expression of
SLE.4
The question which arises is whether the
clinical and immunological manifestations of
SLE in men differ from those in women. This is
important because examination of more homo-
geneous subsets, such as male patients, may
allow for earlier diagnosis, better treatment, and
more accurate prognosis. Several workers have
addressed this problem with controversial
results.' %8 This is probably due to the small
numbers of affected men in the various studies.
To determine whether any relation between
disease pattern and sex exists we have prospec-
tively analysed the clinical manifestations and
immunological features of 30 men from a series
of 261 unselected patients with SLE with
special emphasis on the clinical course during
follow up.
Patients and methods
PATIENTS
We studied prospectively 261 patients with SLE
who were seen consecutively at the Hospital
Clinic of Barcelona either as inpatients or
outpatients between 1980 and 1990. All were
white and met the American Rheumatism Asso-
ciation revised criteria for SLE.9 Thirty (12%)
were men and they represent the male group
described in this paper. Follow up ranged
between two months and 10 years (mean (SD)
64 (55) months) with no significant differences
between the male and female groups.
A detailed clinical and laboratory assessment
according to a pre-established method was
performed on each patient and salient features
included: (a) age at diagnosis; (b) evidence of
clinical renal disease (abnormal urine sediment,
proteinuria greater than 500 mg/day, or other-
wise unexplained increase in serum creatinine
>110I,mol/l); (c) chronic renal failure; (d)
central nervous system disease; (e) cutaneous
disease (including malar rash with fixed
erythema, flat or raised, over the malar emi-
nences, tending to spare the nasolabial folds;
discoid lesions consisting of erythematosus
raised patches with adherent keratocic scaling
and follicular plugging-atrophic scarring may
occur in older lesions; and subacute cutaneous
lesions such as photosensitive, non-scarring
dermatitis appearing as papulosquamous
(psoriasiform) or annular lesions); (I) serositis
(including pleuritis, pericarditis, or both); and
(g) Raynaud's phenomenon.
The disease was judged to be clinically active
when one or more of the following signs or
symptoms were present: typical acute dermatitis;
arthritis; serositis; central nervous system
abnormalities (recent onset of chorea, seizures,
psychosis, organic brain syndrome in the
absence of offending drugs, known metabolic
derangements, or embolic cerebral vascular
accidents); thrombocytopenia (<I00x 109/1);
haemolytic anaemia; vasculitis (biopsy proved);
or nephritis (recent onset of hematuria (> 10 red
blood cells/high power field) or casts, or
proteinuria >500 mg/24 hours or a 25% increase
in serum creatinine). The histological appearance
of renal biopsy specimens was considered to be
active when fresh cellular crescents, diffuse or
focal active proliferation of endocapillary cells,
tuft necrosis, capillary thrombosis, or vasculitis
was present.
LABORATORY STUDIES
Antinuclear antibodies were determined by
indirect immunofluorescence using mouse liver
as substrate. Antibodies to double stranded
DNA were determined with Farr's ammonium
sulphate precipitation technique. Complement
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components (C3 and C4) were estimated by the
radial immunodiffusion method and CH50 by
the Lachmann's haemolytic technique. Circu-
lating immune complexes were detected by the
microcomplement consumption test.
In addition 190 patients were tested for the
presence of precipitating antibodies to soluble
nuclear and cytoplasmic antigens, including
Ro(SSA), La(SSB), nRNP and Sm by double
immunodiffusion (Ouchterlony). These patients
were also tested for the presence of antiphos-
pholipid antibodies, including anticardiolipin
antibodies and the lupus anticoagulant activity.
The anticardiolipin antibodies were measured
by an enzyme linked immunosorbent assay
(ELISA) method as described by Gharavi et
al 10 with minor modifications." The lupus
anticoagulant activity was detected by the
method of Exner et al. 12
STATISTICAL ANALYSIS
Conventional x2 and Fisher's exact tests were
used for analysing qualitative differences,
Student's test for comparison of means in large
samples of similar variance, and the non-
parametric Mann-Whitney U test for small
samples for age differences between groups.
Results
PATIENTS
Of the 261 patients with SLE 30 were men
(12%, female/male ratio 7 7/1). The mean age of
this group at disease onset was 34 years (range
14 64) compared with 31 years (range six-78) in
the women (difference not significant). No
clinical signs of any disturbance in sexual
development were observed in any of them. The
interval between the time of onset and the
diagnosis of SLE was 79 months in the men
compared with 70 months in the women (dif-
ference not significant).
CLINICAL MANIFESTATIONS
The main clinical manifestations at disease
onset for both male and female patients with
SLE are shown in table 1. The men showed
arthritis less often as a first symptom (40 v 64%;
p<0025). Additionally malar rash was less
common in men at disease onset (17 v 31%),
Table I Clinical features at the onset of disease in male
and female patients with SLE. Results given as No (%) of
patients
Men Women
Manifestations (n=30) (n=231) p Value*
Arthritis 12 (40) 147 (64) <0 025
Discoid lesions 5 (17) 3 (1) <0 001
Subacute lesions 1 (3) 6 (3) NS
Malar rash 5 (17) 71 (31) NS
Photosensitivity 6 (20) 40 (17) NS
Raynaud's phenomenon 7 (24) 40 (17) NS
Vasculitis 1 (3) 11 (5) NS
Serositis 7 (23) 23 (10) <0 025
Nephritis 1 (3) 16 (7) NS
Pneumopathy 0 (0) 6 (3) NS
Myositis 1 (3) 10 (4) NS
Cardiovascular disease 0 (0) 11 (5) NS
Neuropsychiatric disease 0 (0) 19 (8) NS
Thrombocytopenia 2 (7) 16 (7) NS
Haemolytic anaemia 1 (3) 7 (3) NS
'NS=not significant.
though this difference did not reach statistical
significance. In contrast the men more often
presented discoid lupus lesions (17 v 1%;
p<0-001) and serositis (23 v 10%; p<0 025).
During the follow up (table 2) analysis of
cumulative clinical symptoms showed that the
most significant difference between these two
groups was again a lower incidence of arthritis
(60 v 81%; p<0-01) and malar rash (23 v 52%;
p<0005) in the men. In contrast this group
showed a significantly increased incidence of
discoid lupus lesions (20 v 3%; p<0-001) and
subacute cutaneous lupus erythematosus (17 v
5%; p<0K025).
The frequency of occurrence of other clinical
features including nephropathy, pulmonary
disease, and central nervous system manifes-
tations did not differ significantly between the
groups.
Two men and 10 women (7 v 4%; p=not
significant) died during the follow up period of
the survey. The causes of death in the men were
lung carcinoma and a multisystem fungal
infection.
IMMUNOLOGICAL ABNORMALITIES
Table 3 gives the immunological findings in
relation to sex. A positive titre of antinuclear
antibodies and antibodies to double stranded
DNA as well as hypocomplementaemia were
common in the two groups, with a similar
proportion of clinically active patients in both
groups. No significant difference between men
and women was found.
The prevalence of antiphospholipid anti-
bodies (anticardiolipin antibodies or lupus
anticoagulant, or both) was similar in the two
groups of patients. In addition no significant
Table 2 Incidence of major clinical features during follow
up of male compared with female patients. Results given
as No (%) of patients
Men Women
Manifestations (n=30) (n=231) p Valuet
Arthritis 18 (60) 188 (81) <0-01
Malar rash 7 (23) 121 (52) <0 005
Discoid lesions 6 (20) 6 (3) <0-001
Subacute lesions 5 (17) 11 (5) <0025
Photosensitivity 9 (30) 71 (31) NS
Raynaud's phenomenon 9 (30) 64 (28) NS
Vasculitis 3 (10) 32 (14) NS
Serositis 11 (37) 67 (29) NS
Nephritis 12 (40) 86 (37) NS
Pneumopathy 2 (7) 11 (5) NS
Myositis 4 (13) 19 (8) NS
Cardiovascular disease 3 (10) 11 (5) NS
Neuropsychiatric disease 0 (0) 27 (12) NS
Thrombocytopenia 7 (23) 50 (22) NS
Haemolytic anaemia 4 (13) 15 (6) NS
*NS=not significant.
Table 3 Serological features at the onset of disease of male
compared with female patients. Results given as mean (SD)
values
Men Women
Parameter (n=30) (n=231) p Value'
dsDNAt (U/ml) 39-6 (34-7) 48-5 (40 9) NS
C3 (mg/I) 796 (262) 677 (285) NS
C4 (mg/I) 266 (155) 221 (144) NS
CH50 (u.u) 415 (212) 377 (196) NS
CIC (%) 22-3 (20 5) 27-1 (21-5) NS
*NS=not significant.
tdsDNA=antibodies to double stranded DNA; CIC=circulatingimmune complexes.
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Table 4 Incidence of antiphospholipid (aPL) antibodies
and antibodies to extractable nuclear antigens at the onset of
disease in male compared with female patients. Results given
as No (%) of patients
Men Women
Parameter (n=25) (n= 180) p Value*
aPL antibodies 11 (37) 69 (30) NS
Ro (SSA) 6 (24) 49 (27) NS
La (SSB) 3 (12) 24 (13) NS
nRNP 4 (16) 32 (18) NS
Sm 6 (24) 34 (19) NS
*NS=not significant.
differences were found in the prevalence of
antibodies to extractable nuclear antigens
between the two groups (table 4).
Discussion
SLE is a systemic autoimmune disorder with a
wide spectrum of clinical and immunological
features. Although it has traditionally been
considered a disease of women, several papers
have described SLE in men.5 6 13 In our series
30 of 261 (12%) patients with SLE were men.
This frequency is similar to that observed by
other workers.' 5 8
Overall experience with male patients with
SLE is not extensive and the precise frequency
of clinical and serological features differs from
study to study. 8 13 14 Miller et al S found that
alopecia, thrombocytopenia, and neurological
disease were less common in male patients than
matched female patients with lupus, although
pleurisy was more common in men. Hochberg
et al 6 noted no significant differences in the
clinical and laboratory manifestations between
male and female patients except for a high
incidence of peripheral neuropathy in male
patients with SLE. Sthoeger et al 7 observed a
higher incidence of neurological disease,
nephritis, thrombocytopenia, vasculitis and
hepatosplenomegaly in male patients. Ward and
Studenski8 found only an increased preqalence
of seizures among men. Kaufman et al 5
reviewed 52 male patients and found an increased
prevalence of renal disease and thrombocyto-
penia. Blum et al 16 also showed a predominance
of renal disease and a lower prevalence of
arthralgia in male patients with SLE.
In our series we have analysed the clinical
expression and immunological features of SLE
in men and women at disease onset and during
the follow up period. This enabled us to observe
several interesting clinical differences. First we
found a lower incidence of arthritis and malar
rash in our male patients as presenting mani-
festations. In contrast this group of patients
had discoid lesions and serositis more often.
This atypical presentation is of paramount
importance because it can lead to a delay in
establishing the correct diagnosis, similar to the
long delay in establishing the diagnosis of SLE
which is common in elderly patients. 7 Secondly,
when we analysed the clinical manifestations
during the follow up period we confirmed a
lower incidence of arthritis and malar rash in
the men and a higher incidence of discoid
lesions, but we also found a higher incidence of
subcutaneous lupus erythematosus. The
incidence of nephropathy, neurological disease,
thrombocytopenia, vasculitis, and serositis, was
similar in the two groups. In addition no
significant immunological differences were
found between men and women.
The discrepancies between this and previous
studies may be due to differences in the criteria
that have been used for the diagnosis of the
clinical manifestations or may reflect the effects
of patient selection or ethnic and racial dif-
ferences. Nevertheless, although this study
could not confirm some of the differences found
by other workers it does support the overall
conclusion of previous workers that several
gender associated differences in the clinical
features of SLE may be present.
Although the explanation for this apparently
sex related variability in SLE expression is still
unclear, a possible key role of sex hormones in
the pathogenesis of SLE has been postulated.
Sex hormones may be important in modifying
SLE expression and in facilitating or suppressing
the disease. 8 Many questions still await further
study from this hormonal perspective, however.
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